CALGARY, Aug. 11, 2014 /CNW/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present at the Wedbush 2014 Life Sciences Conference in a session on Tuesday August 12th, 2014 at 8:35 a.m. ET. The conference takes place on August 12th and 13th at the Le Parker Meridien in New York, NY.
A live audio link to the webcast session will be available at: http://wsw.com/webcast/wedbush28/oncy.
Dr. Thompson is also presenting at the Canaccord Genuity 34th Annual Growth Conference in a session on Wednesday August 13th, 2014 at 1:30 p.m. ET. The conference takes place on August 13th and 14th at the Intercontinental Hotel in Boston, MA.
A live audio link to the webcast session will be available at: http://wsw.com/webcast/canaccord14/oncy.
Links to the presentations will also be available on the company's website at: http://www.oncolyticsbiotech.com/for-investors/presentations. It is recommended that listeners log on 10 minutes in advance of a live presentation to register and download any necessary software. Links to the audio replays will be accessible following the presentations on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
The session and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE: Oncolytics Biotech Inc.
For further information: The Equicom Group, Nick Hurst, 300 5th Ave. SW, 10th Floor, Calgary, Alberta, T2P 3C4, Tel: 403.218.2835, Fax: 403.218.2830, [email protected]; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd Floor, New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, [email protected]